Adherence Monitoring for Substance Abuse Clinical Trials

Information

  • Research Project
  • 8315218
  • ApplicationId
    8315218
  • Core Project Number
    R43DA033712
  • Full Project Number
    1R43DA033712-01
  • Serial Number
    033712
  • FOA Number
    PA-11-096
  • Sub Project Id
  • Project Start Date
    8/1/2012 - 12 years ago
  • Project End Date
    4/30/2013 - 11 years ago
  • Program Officer Name
    AKLIN, WILL
  • Budget Start Date
    8/1/2012 - 12 years ago
  • Budget End Date
    4/30/2013 - 11 years ago
  • Fiscal Year
    2012
  • Support Year
    01
  • Suffix
  • Award Notice Date
    7/31/2012 - 12 years ago
Organizations

Adherence Monitoring for Substance Abuse Clinical Trials

DESCRIPTION (provided by applicant): The evaluation and selection of safe and effective pharmacotherapies for drug abuse and addiction is performed through clinical trials that rely on patients taking the studied medication at the specified time and frequency. To ensure accurate efficacy measures, adherence to the prescribed regimen must be known. Creare proposes to develop an adherence monitoring system to report both timing and dosage information in near-real time during these clinical trials. The Creare system includes confirmatory biomarkers to ensure accuracy of the adherence measures. It can be combined with other assessments linked to dosing time that provide additional measures of efficacy of the test compound over time. During Phase I, we will demonstrate the feasibility of our monitoring system by implementing an initial prototype, performing a pilot human subject test to demonstrate feasibility, and designing a prototype system for implementation and testing during Phase II. The Creare team is well qualified to successfully develop and commercialize this system thanks to algorithms and software Creare has previously developed for image processing, neuropsychological testing, data sharing, and assessment. Our clinical collaborator, Dr. John Mendelson, head of the Addiction and Pharmacology Research Laboratory at the California Pacific Medical Center Research Institute (APRL- CPMCRI) has extensive experience in clinical trials with illicit drug users and pioneered the methods used in our proposed system. PUBLIC HEALTH RELEVANCE: Chronic drug abuse affects not only the health of the users, but also the quality of life of their families, the lives of crime victims, and car crashes caused y drivers under the influence of illicit drugs, and it weighs heavily on the law enforcement agencies and justice system. The proposed real-time, cellular phone-based medication adherence measure will greatly increase the accuracy of clinical trials for substance abuse pharmacotherapies likely to increase effective treatment options for substance abusers, thereby reducing the burden of substance abuse disorders on our society.

IC Name
NATIONAL INSTITUTE ON DRUG ABUSE
  • Activity
    R43
  • Administering IC
    DA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    149498
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    279
  • Ed Inst. Type
  • Funding ICs
    NIDA:149498\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    CREARE, LLC
  • Organization Department
  • Organization DUNS
    072021041
  • Organization City
    HANOVER
  • Organization State
    NH
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    037550071
  • Organization District
    UNITED STATES